Drugmakers Are Discovering The High Cost Of Cutting CostsJoseph Weber
When Dr. Leon E. Rosenberg was contemplating his move from dean of the Yale School of Medicine to head of research and development at Bristol-Myers Squibb three years ago, the pharmaceutical industry looked like research nirvana. "Research and development funding was increasing at double digits," he recalls. There were 4,000 scientists and technicians at the company's lavish research institute in Princeton, N.J., when Rosenberg came on board--and the plan was for that number to soon top 5,000.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- This $14 Million Atlanta Home With Bunker Is ‘Safest in America’
- These Cities Make NYC Housing Look Dirt Cheap
- GE's New CEO Vows Sweeping Change After ‘Unacceptable’ Report
- Separatists Pledge to Fight On After Spain Moves to Oust Catalan Leaders
- The U.K.'s $86 Billion Pension Problem Is About to Solve Itself